Clinical presentation and treatment of migraine

Clinical Therapeutics

Volumn 18, Issue 2, 1996, Pages 229-245

  Skaer, Tracy L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORPROMAZINE; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOTAMINE; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; KETOROLAC; MEFENAMIC ACID; METOCLOPRAMIDE; NAPROXEN; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PARACETAMOL; SEROTONIN AGONIST; SUMATRIPTAN; TOLFENAMIC ACID; VASOACTIVE AGENT;

BRAIN BLOOD FLOW; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DYSPEPSIA; DYSTONIA; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIFESTYLE; MIGRAINE; PHYSICAL ACTIVITY; PHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TARDIVE DYSKINESIA; TRIGEMINAL NERVE; VASODILATATION;

EID: 0029952278     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80004-X     Document Type: Article

References (71)

1. Headache Classification Committee of International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(Suppl 7):1-96.
2. Stewart W, Lipton R, Celentano D, Reed M. The epidemiology of severe migraine headaches from a national survey: Implications of projections to the US population. Cephalalgia. 1991;11(Suppl 11):87-88.
3. Dechant KL, Clissold SP. Sumatriptan: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992;43: 776-798.
4. Plosker GL, McTavish D. Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
5. Solomon S, Lipton RB, Newman LC. Migraine: Clinical features and diagnosis. Compr Ther. 1992;18:24-27.
6. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attack: A double-blind study. Cephalalgia. 1984;4:107-111.
7. Peatfield RC, Petty RG, Rose FC. Double-blind comparison of mefenamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia. 1983;3:129-143.
8. Hakkarainen H, Gustafsson B, Stockman O. A comparative trial of ergotamine tartrate, acetylsalicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache. 1978;18:35-39.
9. Somerville BW. Treatment of migraine attacks with an analgesic combination (Mersyndol). Med J Aust. 1976;1:865-866.
10. Rapoport A, Weeks R, Sheftell F. Analgesic rebound headache: Theoretical and practical implications. Cephalalgia. 1985; 5(Suppl 3):448-449.
11. Havanka-Kanniainen H. Treatment of acute migraine attack: Ibuprofen and placebo compared. Headache. 1989;29: 507-509.
12. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia. 1985;5:5-10.
13. Pradalier A, Rancurel G, Dordain S, et al. Acute migraine attack therapy: Comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia. 1985; 5:107-113.
14. Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: Naproxen and placebo compared. Cephalalgia. 1985;5:115-119.
15. Larsen BH, Christiansen LV, Andersen B, Oleson J. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand. 1990; 81:464-467.
16. Carasso RL, Peled O, Yehuda S. Flufenamic acid in prostaglandin migraine. Int J Neurosci. 1985;27:67-71.
17. Awidi AS. Efficacy of flurbiprofen in the treatment of acute migraine attacks. Curr Ther Res. 1982;32:492-497.
18. Karachalios GN, Fotiadou A, Chrisikos N, et al. Treatment of acute migraine attack with diclofenac sodium: A double-blind study. Headache. 1992;32:98-100.
19. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992;12:169-171.
20. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. Headache. 1993;33:560-562.
21. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-171.
22. Schmidt R, Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol. 1974;7:213-216.
23. Hakkarainen H, Allonen H. Ergotamine vs. metoclopramide vs. their combination in acute migraine attacks. Headache. 1982;22:10-12.
24. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet. 1985;10: 334-352.
25. Fullerton T, Gengo FM. Sumatriptan: A selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother. 1992;26: 800-808.
26. 1-like receptor agonist for the acute treatment of severe migraine. Lancet. 1988;1:1309-1311.
27. Perrin VL, Farkkila M, Gosguen J, et al. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia. 1989;9(Suppl 9): 63-72.
28. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265: 2831-2835.
29. The Oral Sumatriptan Dose-Defining Group. Sumatriptan - an oral dose-defining study. Eur Neurol. 1991;31:300-305.
30. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:306-331.
31. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338:782-783.
32. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. NEJM. 1991;325: 316-321.
33. Visser WH. Does a combined regimen of subcutaneous followed by oral sumatriptan prevent headache recurrence? Cephalalgia. 1993;13(Suppl 13):189.
34. Hulme A, Dalton DW. The efficacy of subcutaneous sumatriptan in the treatment of headache recurrence. Cephalalgia. 1993; 13(Suppl 13):157.
35. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: An overview. Eur Neurol. 1991;31:339-344.
36. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31: 323-331.
37. Willett F, Curzen N, Adams J, Armaitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ. 1992;304: 1415.
38. Ottervanger JP, Paalman HJA, Boxma GL, Stricker BHCh. Transmural myocardial infarction with sumatriptan. Lancet. 1993; 341:861-862.
39. Curtin T, Brooks AP, Roberts JA. Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992;305: 713-714.
40. Fowler P, Lacey L, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
41. ® injection labeling. Cerenex Pharmaceuticals, Division of Glaxo Wellcome, Inc, Research Triangle Park, NC; December 1992.
42. Hsu VD. Criteria for use of sumatriptan in adult inpatients and outpatients. Clin Pharm. 1992;11:972-974.
43. Tek DS, McClellan DS, Olskaer JS, et al. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19: 1083-1087.
44. Lan PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 1989;18:360-365.
45. Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine attacks. Ann Emerg Med. 1990;19:1079-1082.
46. Jones S, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989;261: 1174-1176.
47. Drummond PD. Effectiveness of methysergide in relation to clinical features of migraine. Headache. 1985;25:145-146.
48. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979; 36:965-969.
49. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. BMJ. 1974;2: 699-701.
50. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol - a comparison with placebo. Cephalalgia. 1987;7(Suppl 6):457-458.
51. Kangasniemi P, Andersen AR, Andersson PG, et al. Classic migraine: Effective prophylaxis with metoprolol. Cephalalgia. 1987;7:231-238.
52. Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache. 1980; 20:204-207.
53. Jonansson V. Atenolol in migraine prophylaxis: A double-blind crossover multicenter study. Headache. 1987;27:372-374.
54. Ryan RE Sr, Ryan RE Jr, Sudilovsky A. Nadolol: Its use in the prophylactic treatment of migraine. Headache. 1983;23: 26-31.
55. Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985;35: 1304-1310.
56. Couch JR, Ziegler DK, Hassanein RS. Evaluation of the relationship between migraine headache and depression. Headache. 1975;15:41-50.
57. Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis in migraine. Headache. 1989;29:215-218.
58. McArthur JC, Marek K, Pestronk A, et al. Nifedipine in the prophylaxis of classic-migraine: A crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology. 1989;39:284-286.
59. Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache. 1983;23:106-109.
60. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia. 1985;5:38-43.
61. Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache. 1983;23:266-277.
62. Stewart DJ, Gelston A, Hakim A. Effects of prophylactic administration of nimodipine in patients with migraine. Headache. 1988;28:260-262.
63. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine: A double-blind, placebo-controlled study. JAMA. 1983;250:2500-2502.
64. Markley HG, Cheronis JCD, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology. 1984;34:973-976.
65. Markley HG. Verapamil and migraine prophylaxis: Mechanisms and efficacy. Am J Med. 1991;90(Suppl 5A):48S-53S.
66. Sargent J, Solbach P, Damasio H. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985;25:320-324.
67. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA. 1990;264:1711-1713.
68. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol. 1969;21:263-268.
69. Sorensen KV. Valproate: A new drug in migraine prophylaxis. Acta Neurol Scand. 1988;78:346-348.
70. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
71. Matthew N, Ali S. Valproate in the treatment of persistent chronic daily headache. Headache. 1991;31:71-74.